Business
Axsome Therapeutics Announces AXS-07 Achieves Co-Primary and Key Secondary Endpoints in MOMENTUM Phase 3 Migraine Trial in Patients with History of Inadequate Response
Demonstrated statistical significance on regulatory co-primary endpoints of pain freedom
About this update from Axsome Therapeutics, Inc.
[{"type":"text","content":"Demonstrated statistical significance on regulatory co-primary endpoints of pain freedom (p","length":113,"tagName":"div"}]